The FN3K-Nrf2 Axis: A Novel Therapeutic Target in Cancer Metabolism
Fructosamine-3-kinase (FN3K) is crucial for cellular metabolism, reversing early glycation products to maintain protein function and cellular homeostasis. Recent research highlights FN3K's role in cancer biology through its interaction with the Nrf2 transcription factor, which regulates cellular antioxidant responses and redox homeostasis. FN3K's deglycation activity can influence Nrf2 function, impacting cancer development and progression. Evidence suggests that FN3K stabilizes Nrf2, promoting the expression of genes involved in cell survival, proliferation, and chemotherapy resistance. Increased FN3K expression in cancers is linked to poor prognosis and treatment resistance, possibly by preventing Nrf2 ubiquitination and degradation. This sustained activation of Nrf2 target genes helps cancer cells bolster their antioxidant defenses and support tumor growth. Understanding the FN3K-Nrf2 interaction offers new therapeutic opportunities. Targeting FN3K-mediated deglycation could modulate Nrf2 activity in cancer, potentially enhancing treatment efficacy and reducing resistance. Further research is needed to clarify the molecular mechanisms and develop specific
inhibitors targeting FN3K in cancer cells. This review aims to provide an overview of FN3K, emphasize its importance in deglycation, and discuss pharmaceutical interventions targeting FN3K to combat cancer.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Can- cer J Clin 2020;70(1):7–30.
2. Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI. Targeting drug chemo-resistance in cancer using natural products. Biomedicines 2021;9(10):1353.
3. Sawyers C. Targeted cancer therapy. Nature 2004;432(7015):294–7.
4. Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med 2022;54(10):1670–94.
5. Liberti MV, Locasale JW. The Warburg effect: How does it ben- efit cancer cells? Trends Biochem Sci 2016;41(3):211–8.
6. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell prolif- eration. Science 2009;324(5930):1029–33.
7. Li J, Eu JQ, Kong LR, Wang L, Lim YC, Goh BC, et al. Targeting metabolism in cancer cells and the tumor microenvironment for cancer therapy. Molecules 2020;25(20):4831.
8. Beeraka NM, Bovilla VR, Doreswamy SH, PuttalingaiahS, Srini- vasan A, Madhunapantula SV. The taming of nuclear factor erythroid-2-related factor-2 (Nrf2) deglycation by fructos- amine-3-kinase (FN3K)-inhibitors—a novel strategy to com- bat cancers. Cancers Basel 2021;13(2):281.
9. Szwergold BS. Intrinsic toxicity of glucose, due to non- enzymatic glycation, is controlled in vivo by deglycation systems including FN3K-mediated deglycation of fructos- amines and transglycation of aldosamines. Med Hypotheses 2005;65(2):337–48.
10. Beeraka NM, Zhang J, Mandal S, Vikram PRH, Liu J, BM N, et al. Screening fructosamine-3-kinase (FN3K) inhibitors, a de- glycating enzyme of oncogenic Nrf2: Human FN3K homol- ogy modelling, docking and molecular dynamics simulations.PLoS One 2023;18:e0283705.
11. Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, et al. The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-kinase. Cell 2019;178(5):807–19.e21.
12. Martins DBG, de Aguiar AC, deAraújo Barbosa FM, Leitão GM. The dual role of NRF2 transcription factor in female cancer. In JA Morales-González, MA Soriano-Ursúa, EO Madrigal-Santil- lán, Á Morales-González. The role of NRF2 Transcription Fac- tor. IntechOpen; 2024.
13. Sartore G, Ragazzi E, Burlina S, Paleari R, Chilelli NC, Mosca A, et al. Role offructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complica- tions in patients with T2DM. BMJ Open Diabetes Res Care 2020;8(1):e001256.
14. Collard F, Delpierre G, Stroobant V, Matthijs G, Van Schaftin- gen E. A mammalian protein homologous to fructosamine- 3-kinase is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 2003;52(12):2888–95.
15. Kannan N, Shrestha S, Taujale R, Kannan N. Illuminating the functions of the understudied fructosamine-3-kinase (FN3K) using a multi-omics approach reveals new links to lipid, carbon, and co-factor metabolic pathways. Res Sq 2024;2024:rs.3.rs-3934957.
16. Ruwali M, Shukla R. Oxidative stress and cancer: Role of the Nrf2-antioxidant response element signaling pathway. In S Chakraborti, BK Ray, S Roychoudhury, editors. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Singapore: Springer Nature; 2022. p. 957–73.
17. Yousefi T, Pasha ARG, Kamrani G, Ebrahimzadeh A, Zahedian A, Hajian-Tilaki K, et al. Evaluation offructosamine-3-kinase and glyoxalase 1 activity in normal and breast cancer tissues. Biomedicine Taipei 2021;11(3):15–22.
18. Caruso MG, Notarnicola M, Altomare DF, Misciagna G. Gene expression offructosamine-3-kinasein patients with colorec- tal cancer. Oncology 2007;73(1–2):72–5.
19. National Cancer Institute. Targeted therapy to treat cancer. Available at: https://www.cancer.gov/about-cancer/treat- ment/types/targeted-therapies. Accessed May 31, 2022.
20. Szwergold BS, Howell SK, Beisswenger P. Nonenzymatic gly- cation/enzymatic deglycation: A novel hypothesis on the eti- ology of diabetic complications. Diabetologia 2002;45(Suppl 1):143–52.
21. Timson DJ. GHMP kinases—structures, mechanisms, and po- tential for therapeutically relevant inhibition. Curr Enzyme In- hib 2007;3(1):77–94.
22. Szwergold BS, HowellS, Beisswenger PJ. Human fructosamine- 3-kinase: Purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 2001;50(9):2139–47.
23. ShresthaS, Katiyar S, Sanz-Rodriguez CE, Kemppinen NR, Kim HW, Kadirvelraj R, et al. A redox-active switch in fructosamine- 3-kinases expands the regulatory repertoire of the protein ki- nase superfamily. Sci Signal 2020;13(639):eaax6313.
24. Delpierre G, Vertommen D, Communi D, Rider MH, Van Schaft- ingen E. Identification offructosamine residues deglycated by fructosamine-3-kinasein human hemoglobin. J Biol Chem 2004;279(26):27613–20.
25. Lokhandwala J, Matlack JK, Smalley TB, Miner RE III, Tran TH, Binning JM. Structural basis for FN3K-mediated protein degly- cation. Structure 2024;32(10):1234–46.
26. Van Schaftingen E, Delpierre G, Collard F, Veiga-da-Cunha M. Fructosamine 3-kinase and other enzymes involved in protein deglycation. Adv Enzyme Regul 2007;47(1):261–9.
27. Shrestha S, Taujale R, Katiyar S, Kannan N. Illuminating the functions of the understudied fructosamine-3-kinase (FN3K) using a multi-omics approach reveals new links to lipid, car- bon, and co-factor metabolic pathways. NPJ Syst Biol Appl 2024;10(1):64.
28. Delplanque J, Delpierre G, Opperdoes FR, Van Schaftingen E. Tissue distribution and evolution of fructosamine 3-ki- nase andfructosamine 3-kinase-related protein. J Biol Chem 2004;279(45):46606–13.
29. Monnier VM. The fructosamine 3-kinase knockout mouse: A tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging. Biochem J 2006;399(2):e21232.
30. Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients 2010;2(12):1247–65.
31. UcedaAB, MariñoL, Casasnovas R,Adrover M. An overview on glycation: Molecular mechanisms, impact on proteins, patho- genesis, and inhibition. Biophys Rev 2024;16:189–218.
32. Ahmed N. Advanced glycation endproducts—role in pa- thology of diabetic complications. Diabetes Res Clin Pract 2005;67(1):3–21.
33. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63(4):582–92.
34. Delpierrre G, Vertommen D, Communi D, Rider MH, Van Schaftingen E. Identification offructosamine residues degly- cated by fructosamine-3-kinasein human hemoglobin. J Biol Chem. 2004;279(26):27613-20.
35. Hammoudi N, Ahmed KB, Garcia-Prieto C, Huang P. Metabolic alterations in cancer cells and therapeutic implications. Chin J Cancer 2011;30(8):508–25.
36. Avemaria F, Carrera P, Lapolla A, Sartore G, Chilelli N, Paleari R, et al. Possible role offructosamine 3-kinase genotyping for the management of diabetic patients. Clin Chem Lab Med 2015;53(9):1315–20.
37. LokhandwalaJ, Tran T, Matlack J, Binning J. Molecular mecha- nismof protein deglycation by fructosamine-3-kinase. J Biol Chem 2024;300(3 Suppl):106955.
38. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degra- dation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011;3(12):a005058.
39. Collard F, Delpierre G, Stroobant V, Matthijs G. A mamma- lian protein homologous to fructosamine-3-kinaseis a ketos- amine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 2004;52(12):2888–95.
40. Li R, Jia Z, Zhu H. Regulation of Nrf2 signaling. React Oxyg Species Apex 2019;8(24):312–22.
41. Rojo dela Vega M, Chapman E, Zhang DD. NRF2 and the hall- marks of cancer. Cancer Cell 2018;34(1):21–43.
42. Katsuoka F, Yamamoto M. Small Maf proteins (MafF, MafG, MafK): History, structure and function. Gene 2016;586(2):123– 8.
43. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary me- tabolism. Trends Biochem Sci 2014;39(4):199–218.
44. Baird L, Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol 2020;40(13):e00099- 20.
45. Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic Biol Med 2015;88(Pt B):108–46.
46. Saha S, Buttari B, Panieri E, Profumo E, Saso L. An overview of Nrf2 signaling pathway and its role in inflammation. Mol- ecules 2020;25(22):5474.
47. Taguchi K, Motohashi H, Yamamoto M. Molecular mecha- nisms of the Keap1–Nrf2 pathway in stress response and can- cer evolution. Genes Cells 2011;16(2):123–40.
48. Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004;24(24):10941–53.
49. Ngo V, Duennwald ML. Nrf2 and oxidative stress: A general overview of mechanisms and implications in human disease. Antioxidants Basel 2022;11(12):2345.
50. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxida- tive stress. Mol Cell Biol 2003;23(22):8137–51.
51. Chen F, Xiao M, Hu S, Wang M. Keap1-Nrf2 pathway: A key mechanism in the occurrence and development of cancer. Front Oncol 2024;14:1381467.
52. Vomund S, Schäfer A, Parnham MJ, Brüne B, von Knethen A. Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci 2017;18(12):2772.
53. HammadM, RaftariM, CesárioR, Salma R, Godoy P, EmamiSN. Roles of oxidative stress and Nrf2 signaling in pathogenic and non-pathogenic cells: A possible general mechanism of resis- tance to therapy. Antioxidants Basel 2023;12(7):1371.
54. Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal 2018;29(17):1727–45.
55. Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 sig- naling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res 2018;1865(5):721–33.
56. Lin L, Wu Q, Lu F, Lei J, Zhou Y, Liu Y, et al. Nrf2 signaling path- way: Current status and potential therapeutic targetable role in human cancers. Front Oncol 2023;13:1184079.
57. Glorieux C, Enríquez C, González C, Aguirre-Martínez G, Buc Calderon P. The multifaceted roles of NRF2 in cancer: Friend or foe? Antioxidants Basel 2024;13(1):70.
58. Tripathi S, Kharkwal G, Mishra R, Singh G. Nuclear factor ery- throid 2-related factor 2 (Nrf2) signaling in heavy metals-in- duced oxidative stress. Heliyon 2024;10(18):e37545.
59. Robledinos-Antón N, Fernández-Ginés R, Manda G, Cuadra- do A. Activators and inhibitors of NRF2: A review of their potential for clinical development. Oxid Med Cell Longev 2019;2019:9372182.
60. Suzen S, Tucci P, Profumo E, Buttari B, Saso L. A pivotal role of Nrf2 in neurodegenerative disorders: A new way for therapeu- tic strategies. Pharmaceuticals Basel 2022;15(6):692.
61. Sagar S, Rajesh C, Radhakrishnan P. Targeting oxidative stress specific Nrf2 in pancreatic cancer stem cells. In ChakrabortiS, editor. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Singapore: Springer; 2022. p. 95.
62. Bassani N. Abstract B019. BRCA1-NRF2 pathway as a new therapeutic target in Ewing sarcoma. Cancer Res 2022;28(18 Suppl):B019.
63. Wu H, Zhong X. Nrf2 as a therapy target for Th17-dependent autoimmune diseases. In JA Morales-González, MA Soriano- Ursúa, EO Madrigal-Santillán, Á Morales-González, editors. The Role of NRF2 Transcription Factor. IntechOpen; 2024.
64. Liu Y, Lang F, Yang C. NRF2 in human neoplasm: Cancer bi- ology and potential therapeutic target. Pharmacol Ther 2021;217:107664.
65. Wu S, Lu H, Bai Y. Nrf2 in cancers: A double-edged sword. Can- cer Med 2019;8(5):2252–61.
66. Zimta AA, Cenariu D, Irimie A, Magdo L, NabaviSM, Atanasov AG, et al. The role of Nrf2 activity in cancer development and progression. Cancers Basel 2019;11(11):1755.
67. Jeddi F, Soozangar N, Sadeghi MR, Somi MH. Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/ promotion and chemoresistance. DNA Repair Amst 2017;54:8.
68. Hu M, Yuan L, Zhu J. The dual role of NRF2 in colorectal can- cer: Targeting NRF2 as a potential therapeutic approach. J In- flamm Res 2024;5985–6004.
69. Pouremamali F, PouremamaliA, Dadashpour M, Soozangar N, Jeddi F. An update of Nrf2 activators and inhibitors in cancer prevention/promotion. Cell Commun Signal 2022;20(1):100.
70. Baiskhanova D, Schäfer H. The role of Nrf2 in the regulation of mitochondrial function and ferroptosis in pancreatic cancer. Antioxidants Basel 2024;13(6):696.
71. Tian Y, Tang L, Wang X, Ji Y, Tu Y. Nrf2 in human cancers: Bio- logical significance and therapeutic potential. Am J Cancer Res 2024;14(8):3935–61.
72. Panieri E, Saso L. Potential applications of NRF2 inhibitors in cancer therapy. Oxid Med Cell Longev 2019;2019:8592348.
73. Jung BJ, Yoo HS, Shin S, Park YJ, Jeon SM. Dysregulation of NRF2 in cancer: From molecular mechanisms to therapeutic opportunities. BiomolTher Seoul 2018;26(1):57–68.
74. Srivastava R, Fernández-Ginés R, EncinarJA, Cuadrado A, Wells G. The current status and future prospects for therapeutic tar- geting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance. Free Radic Biol Med 2022;192:246–60.
75. Zhang J, Xu HX, Zhu JQ, Dou YX, XianYF, Lin ZX. Natural Nrf2 inhibitors: A review of their potential for cancer treatment. Int J Biol Sci 2023;19(10):3029–41.
76. NamaniA, Li Y, Wang XJ, Tang X. Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer. Bio- chim Biophys Acta Mol Cell Res 2014;1843(9):1875–85.
77. Krajka-Kuźniak V, Baer-Dubowska W. Modulation of Nrf2 and NF-κB signaling pathways by naturally occurring com- pounds in relation to cancer prevention and therapy. Are combinations better than single compounds? Int J Mol Sci 2021;22(15):8223.
78. Agrawal M, Agrawal SK. Implications of NRF2 in cancer pro- gression and therapeutics. In ChakrabortiS, editor. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects. Singapore: Springer; 2022.
79. Telkoparan-Akillilar P, Suzen S, Saso L. Pharmacological appli- cations of Nrf2 inhibitors as potential antineoplastic drugs. Int J Mol Sci 2019;20(8):2025.
80. Lin H, Qiao Y, Yang H, Nan Q, Qu W, Feng F, et al. Small mo- lecular Nrf2 inhibitors as chemosensitizers for cancer therapy. Future Med Chem 2020;12(3):243–67.
81. Tong X, Pelling JC. Targeting the PI3K/Akt/mTOR axis by api- genin for cancer prevention. Anticancer Agents Med Chem 2013;13(7):971–8.
82. Lu Y, SunY, Zhu J, Yu L, Jiang X, Zhang J, et al. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway. Cell Death Dis 2018;9(1):15.
83. Kumar H, Kumar RM, Bhattacharjee D, Somanna P, Jain V. Role of Nrf2 signaling cascade in breast cancer: Strategies and treatment. Front Pharmacol 2022;13:720076.
84. Liu B, Wang H. Oxaliplatin induces ferroptosis and oxidative stress in HT29 colorectal cancer cells by inhibiting the Nrf2 signaling pathway. Exp Ther Med 2022;23(6):11321.
85. Beeraka NM, Zhang J, Zhao D, Liu J, U CA, Vikram PR, et al. Combinatorial implications of Nrf2 inhibitors with FN3K inhibitor: In vitro breast cancer study. Curr Pharm Des 2023;29(30):2408–25.
86. Bai Y, You Y, Chen D, Chen Y, Yin Z, Liao S, et al. Amiloride re- duces fructosamine-3-kinase expression to restore sunitinib sensitivity in renal cell carcinoma. iScience 2024;27(6):109997.
87. Park JS, Rustamov N, Roh YS. The roles of NFR2-regulated oxi- dative stress and mitochondrial quality control in chronic liver diseases. Antioxidants Basel 2023;12(11):1928.
88. He F, Antonucci L, Karin M. NRF2 as a regulator of cell me- tabolism and inflammation in cancer. Carcinogenesis 2020;41(4):405–16.
89. Palanissami G, Paul SFD. AGEs and RAGE: Metabolic and mo- lecular signatures of the glycation-inflammation axis in ma- lignant or metastatic cancers. Explor Target Antitumor Ther 2023;4(5):812–49.
90. Ryoo I, Lee S, Kwak MK. Redox modulating NRF2: A potential mediator of cancer stem cell resistance. Oxid Med Cell Longev 2015;2016:2428153.
91. Tang YC, Chuang YJ, Chang HH, Juang SH, Yen GC, Chang JY, et al. How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy. J Food Drug Anal 2023;31(3):387–407.
92. Sivinski J, Zhang DD, Chapman E. Targeting NRF2 to treat can- cer. Semin Cancer Biol 2021;76:61–73.
93. Robertson H, Dinkova-Kostova AT, Hayes JD. NRF2 and the ambiguous consequences of its activation during initiation and the subsequent stages of tumourigenesis. Cancers Basel 2020;12(12):3609.
94. Cirone M, D'Orazi G. NRF2 in cancer: Cross-talk with oncogen- ic pathways and involvement in gammaherpesvirus-driven carcinogenesis. IntJ Mol Sci 2022;24(1):595.
95. Beeraka NM, Zhang J, Chinnappa AU, Churganova AA, Liu J, Vikram PRH, et al. Expression patterns and relevance of FN3K, Nrf2, and NQO1 in breast cancers. EJMO 2024;8(1):88–105.
96. Ghareghomi S, Habibi-Rezaei M, Arese M, Saso L, Moosavi- MovahediAA. Nrf2 modulation in breast cancer. Biomedicines 2022;10(10):2668.
97. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: Advances, challeng- es, and future perspectives. Signal Transduct Target Ther 2021;6(1):201.
98. Van Schaftingen E, Delpierre G, Collard F, Veiga-da-Cunha M. Fructosamine 3-kinase and other enzymes involved in protein deglycation. Adv Enzyme Regul 2007;47(1):261–9.
99. Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK path- way for cancer therapy: From mechanism to clinical studies. Signal Transduct Target Ther 2023;8(1):455.